Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Targeted radioligand therapy of metastatic castration-resistant prostate cancer (mCRPC) with Lu-PSMA (RLT) requires sufficient dose monitoring of the kidneys. Currently, dosimetry using SPECT/CT-imaging is the most preferred method. However, SPECT/CT is a time-consuming procedure and comprises additional radiation exposure to the patient. Moreover, not every therapeutic nuclear medicine facility has access to SPECT/CT. Therefore, the aim of this study was to develop a new procedure of kidney dosimetry without the use of SPECT/CT and evaluate this method in a large cohort of patients with mCRPC undergoing RLT.
Procedures: A dedicated torso phantom with kidneys filled with a solution of Lu-PSMA was used for quantitative calibration of a SPECT-camera. The calculated sensitivity was adapted according to the individual attenuation of the patient in four directions from the kidney surface to the body surface (ventral, dorsal, left and right) obtained from a previously performed CT. A total of 196 patients undergoing 926 cycles of Lu-PSMA therapy were retrospectively analyzed. Abdominal SPECT was performed 24, 48 and 72 h after administration of Lu-PSMA including scatter and dead-time correction in every patient. Kidney dose was calculated using an individual attenuation-based procedure and compared to values from international literature.
Results: Volumes of interest of the kidneys were drawn in the three sequential SPECT-images to calculate intra-renal effective half-life. Absolute quantification of activity in the kidneys was accomplished obtaining a patient individual sensitivity based on the individual attenuation in the patient. Kidney dose was then calculated applying a bi-exponential time activity curve in Microsoft EXCEL. Mean kidney dose per administered activity was 0.54 (± 0.26) Gy/GBq.
Conclusions: With the presented procedure a reliable kidney dosimetry is possible without the use of SPECT/CT. Facilities without SPECT/CT are therefore able to perform an adequate kidney dosimetry without additional radiation exposure for the patient.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162791 | PMC |
| http://dx.doi.org/10.1007/s11307-025-01998-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study.
Nuklearmedizin
September 2025
Nuclear Medicine, Ulm University Hospital, Ulm, Germany.
Silicon-based ligands are of interest in increasingly used Prostate-specific membrane antigen (PSMA) tracers for prostate cancer (PCa) staging due to their simple and scalable production. Here, we present first data on dosimetry and biodistribution of the novel PSMA-specific tracer [¹⁸F]siPSMA-14.Seven PCa patients referred for PSMA-PET/CT imaging were imaged at 60 and 120 min p.
View Article and Find Full Text PDFValidation of the collapsed-cone superposition for whole-body patient-specific dosimetry in [177Lu]Lu-PSMA-617 radionuclide therapy.
Med Phys
August 2025
QuantIF AIMS, University of Rouen, Rouen, France.
Background: Patient-specific dosimetry in radiopharmaceutical therapy (RPT) offers a promising approach to optimize the balance between treatment efficacy and toxicity. The introduction of 360° CZT gamma cameras enables the development of personalized dosimetry studies using whole-body single photon emission computed tomography and computed tomography (SPECT/CT) data.
Purpose: This study proposes to validate the collapsed-cone superposition (CCS) approach against Monte Carlo (MC) simulations for whole-body dosimetry of [177Lu]Lu-PSMA-617 therapy in patients with metastatic castration resistant prostate cancer (mCRPC).
Can intraoperative endoscopic evaluation replace postoperative low-dose CT for assessing the stone-free status in vacuum-assisted dedusting lithotripsy.
World J Urol
September 2025
Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi District, Tianjin, 300211, People's Republic of China.
Purpose: To compare the diagnostic accuracy of intraoperative endoscopic assessment with postoperative low-dose computed tomography (LDCT) for determining stone-free status (SFS) following retrograde vacuum-assisted dedusting lithotripsy (VADL) using a tip-flexible vacuum-assisted suction ureteral access sheath (tFVS-UAS) and evaluate the feasibility of replacing routine LDCT with intraoperative evaluation.
Methods: This single-center retrospective study analyzed 1,105 patients undergoing unilateral VADL (December 2022-December 2024). All VADL procedures were performed retrograde using tFVS-UAS.
Optimizing dosimetry in Y-90 microsphere radioembolization: GPU-accelerated Monte Carlo simulation versus conventional methods for high-volume setting.
EJNMMI Phys
September 2025
Department of Engineering Physics, Tsinghua University, Beijing, 100084, P. R. China.
Background: Yttrium-90 (Y) microsphere radioembolization has shown unique advantages in treating both primary and metastatic liver cancer and was introduced into China in 2022. Despite the development of various dosimetric models-ranging from empirical to voxel-based approaches-practical implementation remains challenging. With over 370,000 new liver cancer cases annually and limited access to certified Y treatment centers, Chinese interventional oncology departments face increasing pressure to balance dosimetric accuracy with clinical efficiency.
View Article and Find Full Text PDFSynthesis, preclinical evaluation, and clinical translation of [Ga]Ga-Asp-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms.
Eur J Nucl Med Mol Imaging
August 2025
Key Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515,
Purpose: Somatostatin receptor subtype 2 (SSTR2) is overexpressed in well-differentiated neuroendocrine neoplasms (NENs) and serves as a key target for positron emission tomography (PET) imaging. While SSTR2 agonists such as [Ga]Ga-DOTA-TATE are widely used clinically, recent evidence suggests that antagonist radioligands can bind more receptor sites without inducing internalization, potentially offering superior imaging performance. Here, we report the synthesis, preclinical validation, and pilot clinical translation of [Ga]Ga-Asp-JR11, a novel SSTR2 antagonist radioligand featuring an -Asp-PEG- linker designed to enhance hydrophilicity and receptor engagement for PET Imaging of NENs.
View Article and Find Full Text PDF